Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
55 participants
INTERVENTIONAL
2021-06-01
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study
NCT03751761
Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer
NCT03724851
Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)
NCT05620628
Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer
NCT03579784
As a Second-line Treatment for Metastatic Gastric Adenocarcinoma Patients, the Safety and Effective of Vactosertib Administration in Combination With Paclitaxel+Ramucirumab is Evaluated, and a Phase 2a Clinical Trial to Biomarkers
NCT04656002
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
vactosertib in combination with durvalumab
single arm study
durvalumab and vactosertib
durvalumab IV Q4W in combination with vactosertib PO bid (5 days a week)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
durvalumab and vactosertib
durvalumab IV Q4W in combination with vactosertib PO bid (5 days a week)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have a performance status of 0-1 on the ECOG Performance Scale.
* Have measurable disease at least one investigator-assessed measurable disease per RECIST v1.1
* Have adequate organ functions
Exclusion Criteria
* Current or prior use of immunosuppressive medication within 14 days before the first dose of study drugs
* Patients weighing \<30kg
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hark Kyun Kim
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hark Kyun Kim
Principle Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Cancer Center
Goyang-si, Gyeonggi-do, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
33737
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.